R

Ruane Clinical Research Group | Los Angeles, CA

Research site
(Unclaimed)
Location
5901 W Olympic Boulevard, Los Angeles, California, United States of America
Site insights

Top conditions

Hepatitis (6 trials)

Fatty Liver (5 trials)

HIV Infections (5 trials)

Non-alcoholic Fatty Liver Disease (5 trials)

Hepatitis A (5 trials)

Top treatments

Lenacapavir
Budigalimab
ABBV-382
Ribavirin
JNJ-73763989
Selonsertib
JNJ-56136379
ABBV-181
Semaglutide
Sofosbuvir

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

5 of 21
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom
Locations recently updated

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling
Human Immuno-deficiency Virus (HIV) Disease
Drug: Budigalimab
Drug: Placebo for Budigalimab

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting
HIV-1 Infection
Drug: B/F/TAF
Drug: ISL

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Enrolling
HIV-1-infection
Drug: Bictegravir
Drug: BIC/LEN FDC

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting
HIV-1-infection
Drug: Optimized Background Regimen (OBR)
Drug: Failing ARV Regimen

Trial sponsors

Gilead Sciences logo

Gilead Sciences (10 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems